A Phase 2 interventional study of LCI699 in Primary Hyperaldosteronism, sponsored by Novartis. Completed at 1 site in France. Open to participants aged 18 Years to 70 Years. Per ClinicalTrials.gov, last updated 2009-08-26.
Sponsored by Novartis · Phase 2, Interventional, and Treatment
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 14 studies in Hyperaldosteronism with a site in France — 5 open to participants now, 6 under way, 1 of them phase 3. Hyperaldosteronism · France.
Among the 14 studies in Hyperaldosteronism with a site in France, this one is the only one that started in 2008, is one of 2 in phase 2, and was the 1st registered.
201 studies on the registry are indexed under Hyperaldosteronism; 91 are open to participants now.
Browse Hyperaldosteronism studies →5 of the 14 studies in Hyperaldosteronism with a site in France are open now. Recruiting first, the newest first:
University Hospital, Toulouse · Sites in France
Ages 18+
Hospices Civils de Lyon · Sites in France
Ages 18+
Institut National de la Santé Et de la Recherche Médicale, France · Sites in France
Ages 18–90
Assistance Publique - Hôpitaux de Paris · Sites in France
Ages 18–90
Assistance Publique - Hôpitaux de Paris · Sites in France
Ages 18–90
A study can be open while its sites in France have not opened yet or have stopped. Only those recruiting at a site in France →
Of the 68 Hyperaldosteronism studies recruiting now, 22 (32%) set no upper age limit and 30 (44%) stop at 75 or younger; 6 take children under 18; 14 take healthy volunteers.
This study: 18 Years to 70 Years · all sexes · no healthy volunteers.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
14 studies; the count open now beside each. This study's row is marked.
First in 2008; this study’s year is marked. 1 started in 2008.
This study's planned enrollment of 12 is below the median of 63 across 94 interventional studies indexed under Hyperaldosteronism.
Median enrollment 105 across the 9 interventional studies, 250 across the 5 observational. Of the 7 that completed or were terminated, 0 (0%) have results posted.
This tab as a report to print or save as PDF → With an account.
2 of 14 have an industry lead sponsor. The 10 most frequent:
Novartis is the lead sponsor of 714 studies on the registry; none are open to participants now.
Novartis has 1 study filed under Hyperaldosteronism — fewer than ten, so there is no comparison to draw.
2 of the studies in Hyperaldosteronism with a site in France that are under way reach primary completion within a year, 1 of them phase 3. Phase 3 first, then by date:
| Study | Primary completion |
|---|---|
| NCT07007793Phase 3AstraZenecaParent Study: A Study to Assess Efficacy and Safety of Baxdrostat in Participants With Primary Aldosteronism Sub-study: A Follow-up Substudy After Completion of the BaxPA Main Study. | 2027-07-27 |
| NCT04439708Institut National de la Santé Et de la Recherche Médicale, FranceBiomarkers and Choroidal Neovascularization | 2027-01-06 |
Add all 2 to your calendar (.ics) → With an account.
Among the 14 studies in Hyperaldosteronism with a site in France, from their registry updates:
This tab as a report to print or save as PDF → With an account.
The purpose of this study is to determine if LCI699, thorough reductions in aldosterone, can lower BP in patients with Primary hyperaldosteronism.
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Exclusion Criteria:
Other protocol-defined inclusion/exclusion criteria may apply
Drug: LCI699
Systolic blood pressure over a 7-week forced titration treatment period
Time frame: 7 weeks
Plasma and urine hormone levels and electrolytes, diastolic blood pressure and drug pharmacokinetics over a 7-week forced titration treatment period
Time frame: 7 weeks
The record gives a start of Jun 2008 and a primary completion of May 2009. It does not say whether these dates are actual or estimated.
How these figures are worked out, and which studies are left out of them.
This study is completed, as verified in Aug 2009. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Studies of the drug tested here: Osilodrostat